Q BioMed Inc (OTCQB: QBIO) Featured in April Issue of PharmaVOICE Magazine

Getting Past the "Pharma Bro"; How Smaller Biotechs Continue to Strive for the Well-Being of Patients

NEW YORK - April 5, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO), a biotechnology acceleration company reports the Company's CEO was featured in an interview in the April issue of PharmaVOICE magazine.

PharmaVOICE magazine, reaching more than 41,000 BPA-qualified life-sciences executives, is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry.

CEO, Denis Corin talks to PharmaVOICE magazine about Martin Shkreli's actions, drug prices and how he and his company are approaching the issues facing biotech innovators now and in the future.

StockNewsNow.com Publishes New SNNLive Video Interview With Q BioMed Inc. (OTC: $QBIO)

LOS ANGELES, CA - March 24, 2016 (Investorideas.com Newswire) StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Denis Corin, Chairman and CEO of Q BioMed Inc. (OTC:QBIO), a biomedical acceleration and development company, according to the Company's website www.QBioMed.com).  

The video interview was recorded on Monday, February 22nd, 2016, at the SeeThruEquity & The Brewer Group's 2nd Annual Innovations Investor Conference 2016 in Miami, FL.

Watch the SNNLive Video Interview on StockNewsNow.com: https://www.youtube.com/watch?v=yWsNUSRpy6Q

Biotech Q&A: President of Q BioMed Inc. (OTCQB: QBIO) Expands on Corporate Update

Denis Corin DiscussesMannin Research Inc’s Leading Glaucoma Drug Candidate MAN-01

March 21, 2016 Point Roberts WA - Investorideas.com, a digital global news source covering leading sectors including medical technology and biotech stocks releases a recent interview with Mr. Denis Corin, President of Q BioMed Inc. (OTCQB: QBIO).  Denis expands on the recent corporate update and Scrip Intelligence Video released in late February. He also comments on recent developments with Mannin Research Inc’s leading glaucoma drug candidate MAN-01.  (In October 2015 Q BioMed Inc. entered into an agreement with Mannin Research to exclusively license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics.)

Read the full interview at:

http://www.investorideas.com/CO/QBIO/news/2016/03211.asp

NXT-ID (NASDAQ: $NXTD) Receives Notice of Allowance on the Unpassword Encryption Patent

MELBOURNE, Fla. - March 21, 2016 (Investorideas.com Newswire) NXT-ID, Inc. (NASDAQ:NXTD) ("NXT-ID" or the "Company"), a company focused on the growing mobile commerce market, announces the receipt of a notice of allowance from the US Patent Office on its "Unpassword" encryption patent. The invention relates generally to authenticating and encrypting information exchanged between two devices. A first device needs to authenticate a second device, before the first device will exchange information with the second device. "We want to be sure that the second device is not a bad guy or a hacker before actually sending sensitive information." David Tunnell, Chief Technology Officer of NXT-ID.

Generally, this data will be gathered during several different information exchanges. A combined authentication score will be generated by the first device based on these exchanges. Then an encryption key is generated by the first device and it is used to encrypt that combined authentication score. The dynamic pairing code is then that encrypted combined authentication score. Both the first and second devices can decrypt the dynamic pairing code. The dynamic pairing code is modified based on subsequent information exchanges between the first and second devices.